Skip to main content
Clinical Trials/NCT05607992
NCT05607992
Completed
N/A

Brief Internet-delivered Exposure-based Therapy to Reduce Post-traumatic Stress Symptoms and Cardiac Anxiety After Acute Coronary Syndrome: a Pilot Randomized Clinical Trial

Karolinska Institutet2 sites in 1 country31 target enrollmentMay 18, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
Psychological Trauma
Sponsor
Karolinska Institutet
Enrollment
31
Locations
2
Primary Endpoint
Seattle Angina Questionnaire
Status
Completed
Last Updated
last year

Overview

Brief Summary

The purpose of the present pilot study is to evaluate the feasibility and potential efficacy of a brief, internet-delivered CBT protocol provided early after acute coronary syndrome (ACS).

Detailed Description

Acute coronary syndrome (ACS; myocardial infarction (MI) or unstable angina (UA)) is one of the leading causes of mortality and health loss globally. ACS is a stressful and potentially life-threatening cardiovascular event, and many patients develop symptoms of post-traumatic stress (PTSS) and cardiac anxiety post ACS, which have been shown to negatively affect patients' long-term cardiovascular prognosis.The aim of the proposed pilot study is to develop and evaluate a brief internet-delivered exposure-based CBT intervention provided early following ACS to reduce ACS-related PTSS, cardiac anxiety. and increase physical activity and quality of life. Patients with recent ACS (≥ 4 weeks to 6 months) and with elevated PTSS and anxiety will be eligible. After informed consent, patients will be randomized to internet-delivered CBT (N=15) or to a wait-list control group (N=15). The treatment is a 5 week, therapist-guided, internet-delivered intervention which includes imaginal exposure, interoceptive exposure, and exposure in-vivo. Assessments will be conducted at baseline, immediate post-treatment, and 2- and 6- months after treatment. The wait-list will be crossed over to CBT after completion of the 2 month follow-up.

Registry
clinicaltrials.gov
Start Date
May 18, 2023
End Date
August 21, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Josefin Särnholm

Principal Investigator, PhD, Lic. psychologist

Karolinska Institutet

Eligibility Criteria

Inclusion Criteria

  • (A) ACS ≥ four weeks to six months before assessment (MI type 1 STEMI/NSTEMI and UA)
  • (B) Age 18-80 years
  • (C) Symptoms of PTSD and/or cardiac anxiety that leads to distress and/or interferes with daily life (PCL5; ≥ 10, CAQ: ≥20)
  • (D) On standard of care medical treatment for the cardiac condition according to Swedish cardiovascular guidelines
  • (E) Ability to read and write in Swedish.

Exclusion Criteria

  • (F) Heart failure with severe systolic dysfunction (ejection fraction ≤ 35%)
  • (G) Significant valvular disease
  • (H) Planned coronary artery bypass surgery or percutaneous interventions
  • (I) Any medical restriction to physical exercise
  • (J) Severe uncontrolled medical illness i.e., advanced cancer
  • (K) Grade 3 hypertension (i.e., blood pressure ≥ 180 systolic and/or 110 diastolic)
  • (L) Severe psychiatric disorder, active suicidal ideations or cognitive impairment that precludes provision of informed consent or study activities
  • (M) Alcohol dependency
  • (N) Ongoing psychological treatment.

Outcomes

Primary Outcomes

Seattle Angina Questionnaire

Time Frame: Baseline to 3 months

A measure of coronary artery disease on five scales: physical limitation scale, anginal stability scale, anginal frequency scale, treatment satisfaction scale, and the disease perception scale. With a score ranging from 0 to 100. A higher score indicating a better quality of life.

Percentage of enrolled participants who complete the treatment

Time Frame: Baseline to 5 weeks

Feasibility of the intervention components will be assessed by \>60% assessed as treatment completers. Descriptive analysis will also provide number of messages and therapist time.

Acceptability: Client satisfaction Questionnaire

Time Frame: Baseline to 5 weeks

Treatment satisfaction, score ranging from 0 to 32, with a higher score indication more satisfaction with the treatment.

Adverse events

Time Frame: Baseline to 5 weeks

Potential adverse reactions to the treatment. Participants will be asked to report and rate the short- and long term discomfort of the adverse event on a scale from 0 ('did not affect me at all') and 3 ('affected me very negatively').

Secondary Outcomes

  • Cardiac anxiety questionnaire(Change over 5 measurement points measured from baseline and weekly for 5 weeks during treatment)
  • Patient Health Questionnaire-9(Baseline to 7 months)
  • Seattle Angina Questionnaire(Change over 5 measurement points measured from baseline and weekly for 5 weeks during treatment)
  • Body Sensation Questionnaire(Baseline to 7 months)
  • Symptom checklist Severity and Frequency Scale (SCL, adapted to coronary artery disease)(Baseline to 7 months)
  • Generalized Anxiety Disorder 7-item(Baseline to 7 months)
  • Perceived stress scale 4-item(Baseline to 7 months)
  • The Godin Leisure-time Exercise and International Physical Activity Questionnaire 1 item on inactivity(Baseline to 7 months)
  • Lifestyle factors: The national Board of health and Welfare questionnaire(Baseline to 7 months)
  • Myocardial infarction behavior questionnaire(Baseline to 7 months)
  • University of Toronto Atrial fibrillation Severity Scale (AFSS)(Baseline to 7 months)
  • The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5(Change over 5 measurement points measured from baseline and weekly for 5 weeks during treatment)
  • 12-Item Short-Form Health Survey(Baseline to 7 months)

Study Sites (2)

Loading locations...

Similar Trials